Results 1 to 10 of about 27,152 (204)

Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review

BMC Medical Genomics, 2022
Background Dysferlinopathy encompasses a group of rare muscular dystrophies caused by recessive mutations in the DYSF gene. The phenotype ranges from asymptomatic elevated serum creatine kinase (hyperCKemia) to selective and progressive involvement of ...
Cecilia Contreras-Cubas, Francisco Barajas-Olmos, Maria Inés Frayre-Martínez, Georgina Siordia-Reyes, Claudia C. Guízar-Sánchez, Humberto García-Ortiz, Lorena Orozco, Vicente Baca   +7 more
doaj   +2 more sources

The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study

SAGE Open Medicine, 2018
Objective: To examine the clinical utility of tumor markers in dermatomyositis/polymyositis patients in Taiwan. Method: Data were collected retrospectively from the database of Taichung Veterans General Hospital in Taiwan from 1998 to 2014.
Chong Hong Lim, Chih-Wei Tseng, Ching-Tsai Lin, Wen-Nan Huang, Yi-Hsing Chen, Yi-Ming Chen, Der-Yuan Chen   +6 more
doaj   +2 more sources

Identification of Palmitoleic Acid Controlled by mTOR Signaling as a Biomarker of Polymyositis

Journal of Immunology Research, 2017
Polymyositis (PM) is a chronic disease characterized by muscle pain, weakness, and increase in muscle-related enzymes, accompanied with inflammations in lymphocytes.
Geng Yin, Ying Wang, Xiao-min Cen, Yuan Yang, Min Yang, Qi-bing Xie   +5 more
doaj   +2 more sources

Polymyositis and dermatomyositis – challenges in diagnosis and management

Journal of Translational Autoimmunity, 2019
Polymyositis (PM) and dermatomyositis (DM) are different disease subtypes of idiopathic inflammatory myopathies (IIMs). The main clinical features of PM and DM include progressive symmetric, predominantly proximal muscle weakness.
Shu-Han Yang, Christopher Chang, Zhe-Xiong Lian   +2 more
doaj   +2 more sources

Carbamoyl phosphate synthetase 1 deficiency manifested in an adult treated with prednisone for polymyositis, and cured by live-donor liver transplantation [PDF]

Molecular Genetics and Metabolism Reports
Carbamoyl phosphate synthetase 1 (CPS1) deficiency (OMIM#237300) is a rare inherited disorder due to complete or partial lack of the CPS1 enzyme. Polymyositis is a relatively rare systemic inflammatory autoimmune disease.
Kazuhiro Yokota, Akira Ohtake, Taro Yamazaki, Takuma Tsuzuki-Wada, Megumi Saito-Tsuruoka, Takuya Fushimi, Kei Murayama, Yuji Akiyama, Toshihide Mimura   +8 more
doaj   +2 more sources

The Prevalence of Various Autoimmune Comorbidities in Patients with Inflammatory Bowel Disease [PDF]

Epidemiologia
Introduction: Patients with inflammatory bowel disease (IBD) are at increased risk of developing other autoimmune disorders due to possible shared genetic, environmental, and immunological mechanisms.
Bipneet Singh, Shivam Kalra, Tejasvini Khanna, Isha Kohli, Vikash Kumar, Aalam Sohal, Divyesh Sejpal   +6 more
doaj   +2 more sources

Epidemiology of Dermatomyositis and Other Idiopathic Inflammatory Myopathies in Northern Spain [PDF]

Biomedicines
Background/Objectives: The epidemiology of dermatomyositis (DM) and other idiopathic inflammatory myopathies (IIMs) remains not well established, especially in the Mediterranean region.
Cristina Corrales-Selaya, Diana Prieto-Peña, David Martínez-López, Fabricio Benavides-Villanueva, Ricardo Blanco   +4 more
doaj   +2 more sources

A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era [PDF]

Frontiers in Immunology
IntroductionVaccinations have had a transformative impact on public health, reducing the incidence of many infectious diseases and increasing survival. However, there remains uncertainty about the potential of vaccines to trigger autoimmune diseases such
Eaman Alhassan, Anna Patnaik, Anna Patnaik, Ejaz A. Shamim, Ejaz A. Shamim, Ejaz A. Shamim, Janardan P. Pandey, Lisa G. Rider, Frederick W. Miller, Frederick W. Miller   +9 more
doaj   +2 more sources

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis

ACR Open Rheumatology, 2022
To assess the efficacy and tolerability of tocilizumab in a multicenter, randomized, double‐blind, placebo‐controlled trial in refractory adult patients with dermatomyositis (DM) and polymyositis (PM).
C. Oddis, H. Rockette, Lei Zhu, D. Koontz, D. Lacomis, Swamy Venturupalli, S. Moghadam-Kia, D. Ascherman, L. Crofford, M. Dimachkie, F. Ernste, David Gazeley, G. Marder, R. Aggarwal   +13 more
semanticscholar   +1 more source

Chest pain in a mid-aged woman, not simply myopericarditis: a case report of anti-Ku positive polymyositis

BMC Cardiovascular Disorders, 2021
Background Anti-Ku is a rare antibody which can be positive in some rheumatic diseases and it might be related to cardiac involvement. Polymyositis is an inflammatory myopathy, and its cardiac involvement seldom presents as myopericarditis and anti-Ku ...
Weiping Tan, Bin Dong, Jincui Gu, Yang Peng, Ruicong Xue   +4 more
doaj   +1 more source